BRCA1 and ovarian carcinoma: Husain et al. (1998) demonstrated that acquisition of further resistance to cisplatin was associated with an increase in the expression of BRCA1 in MCF-7 cells. In a previous report on human ovarian cancer cells, up-regulation of BRCA1 was associated with more resistance to cisplatin, and the suppression of BRCA1 using its antisense oligonucleotide restored cisplatin sensitivity (Husain et al. 1998).